일본과 해외의 조사회사나 출판사로부터 출판된 산업 조사 보고서 및 데이터 판매 · 연간 서비스 · 맞춤 정보 제공 ChosaReport-Korea 주식회사 SEMABIZ

면역측정 (Immunoassay) 시장조사 보고서

조사회사 : MarketsandMarkets (마켓츠앤마켓츠)   출판년월 : 2023년10월

Immunoassay Market – Global Forecast to 2028

면역측정 (Immunoassay) 시장 : 제품(시약 및 키트, 분석기), 기술(ELISA, CLIA, 신속 검사), 시료(혈액, 타액, 소변), 용도(감염, 내분비학), 최종 사용자(병원 및 클리닉, 혈액 은행), 지역별 – 2028년까지의 세계 예측
Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, CLIA, Rapid Tests), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Endocrinology), End User (Hospitals & Clinics, Blood Banks) & Region – Global Forecast to 2028

페이지 수 382
도표 수 361
구성 영문조사보고서
가격

    주문/문의    납기/라이센스안내

Report Overview

The global immunoassay market is valued at an estimated USD 35.0 billion in 2023 and is projected to reach USD 46.7 billion by 2028, at a CAGR of 5.9% during the forecast period. Market growth is driven by factors such as the rising prevalence of chronic and infectious diseases, innovations in the systems and technologies, supportive government policies and initiatives, and increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing.

면역측정 (Immunoassay) 시장조사 보고서

“The reagents & kits to register the largest share of the immunoassay market, by product.”
The global immunoassay market is segmented into reagents & kits and analyzers based on product. Market growth is largely driven by the repetitive use of reagents & kits for various diagnostic procedures coupled with the increase in the volume of immunoassay-based tests conducted worldwide. Moreover, the availability of better reagents & kits that offer efficient results and precision in diagnosis attributes to their growing requirement resulting in growth of the segment.


“Chemiluminescence Immunoassay segment to grow at a considerable rate among technology during the forecast period.”
The immunoassay market is segmented into ELISA, Chemiluminescence Immunoassay (CLIA), Immunofluorescence assay (IFA), rapid tests, ELISpot, western blotting, and other technologies. CLIA tests help efficiently diagnose various chronic and infectious diseases compared to other techniques such as ELISA and radioimmunoassays, owing to benefits such as sensitivity, wide dynamic range, better speed, reduced interference, and high specificity.


“Infectious diseases segment accounted for the largest share in the immunoassay market, by application.”
The global immunoassay market is segmented into infectious diseases, cardiology, endocrinology, oncology, bone & mineral disorders, autoimmune disorders, blood screening, allergy diagnostics, drug monitoring and testing, newborn screening, and other applications. The application segment of infectious diseases accounted for a considerable share in 2022, primarily due to the rapid diagnosis of infectious diseases coupled with the increasing incidence of diseases such as HIV/AIDS, malaria, hepatitis, and influenza, among others.

“Asia Pacific: The fastest-growing region in the immunoassay market.”
The global immunoassay market is segmented into five regions – North America, Europe, the Asia Pacific, the Middle East & Africa, and Latin America. The Asia Pacific region is expected to grow at the highest rate during the forecast period in the immunoassay market. The high growth in the region is due to the presence of a large target population, and rising prevalence of chronic disorders in Asian countries.

면역측정 (Immunoassay) 시장조사 보고서 - region


The break-up of the profile of primary participants in the immunoassay market:

• By Company Type: Tier 1 – 28%, Tier 2 – 41%, and Tier 3 – 31%
• By Designation: C-level – 30%, D-level – 34%, and Others – 36%
• By Region: North America – 38%, Europe – 27%, Asia Pacific – 18%, Latin America – 6% and Middle East & Africa – 11%,


The key players in this market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), bioMérieux (France), QIAGEN N.V. (Germany), Sysmex Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., LTD. (China), Agilent Technologies (US), Merck KGaA (Germany), Meridian Bioscience (US), Bio-Techne (US), Cellabs (Australia), Abnova Corporation (Taiwan), J. Mitra & Co. Pvt. Ltd. (India), Tosoh Corporation (Japan), Cell Sciences (US), Enzo Biochem (US), Creative Diagnostics (US), Boster Biological Technology (US), Elabscience (US), WAK-Chemie Medical GmbH (Germany), Sera Care (US), Epitope Diagnostics Inc. (US), Kamiya Biomedical Company (US), Gyros Protein Technologies (Sweden), Trivitron Healthcare (India), InBios International Inc. (India), and Maccura Biotechnology Co., Ltd. (China).

면역측정 (Immunoassay) 시장조사 보고서 - ecosystem


Research Coverage:
This research report categorizes the immunoassay market by product (reagents & kits and analyzers), specimen type (blood, urine, saliva, and other specimens), technology (enzyme-linked immunosorbent assays, rapid tests, chemiluminescence immunoassay, immunofluorescence assay, enzyme-linked immunospot, western blotting, and other technologies), application (infectious diseases, blood screening, oncology, endocrinology, bone and mineral disorders, autoimmune disorders, cardiology, drug monitoring and testing, allergy diagnostics, newborn screening, and other applications), end user (clinical laboratories, hospitals and clinics, research & academic laboratories, blood banks, pharmaceutical and biotechnology companies & CROs, and home care settings), and region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the immunoassay market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, and recent developments associated with the immunoassay market. This report covers the competitive analysis of upcoming startups in the immunoassay market ecosystem.

Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall immunoassay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.


The report provides insights on the following pointers:
• Analysis of key drivers (incidence of chronic and infectious diseases and growing awareness about early disease diagnosis, in systems and technologies, growth in biotechnology and biopharmaceutical industries, increasing adoption of immunoassay-based POC testing and rapid testing, supportive government policies, and increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing), restraints (requirements for approval of immunoassay instruments and consumables and technical hurdles of immunoassay kits), opportunities (opportunities in emerging economies, importance of companion diagnostics, development of condition-specific biomarkers and tests, integration of microfluidics in immunoassays, and improving immunoassay diagnostic technologies), and challenges (design challenges, complexities, and quality of antibodies, dearth of skilled professionals, unfavourable reimbursement scenario, and financial hurdles faced by physicians) influencing the growth of the immunoassay market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the immunoassay market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the immunoassay market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the immunoassay market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), and Thermo Fisher Scientific Inc. (US)among others in the immunoassay market strategies. 

Table of Contents

1            INTRODUCTION            40

1.1         STUDY OBJECTIVES      40

1.2         MARKET DEFINITION   40

1.3         INCLUSIONS & EXCLUSIONS     41

1.4         MARKET SCOPE             42

1.4.1      MARKETS COVERED     42

FIGURE 1           IMMUNOASSAY MARKET SEGMENTATION        42

1.4.2      REGIONS COVERED      43

1.4.3      YEARS CONSIDERED     43

1.4.4      CURRENCY CONSIDERED          44

1.5         STAKEHOLDERS            44

1.6         SUMMARY OF CHANGES            44

1.6.1      IMPACT OF RECESSION: IMMUNOASSAY MARKET          45

2            RESEARCH METHODOLOGY     46

2.1         RESEARCH DATA           46

FIGURE 2           RESEARCH DESIGN       46

2.1.1      SECONDARY RESEARCH             47

2.1.1.1   Key data from secondary sources     48

2.1.2      PRIMARY RESEARCH     48

2.1.2.1   Primary sources   48

2.1.2.2   Key data from primary sources         49

2.1.2.3   Key industry insights          50

FIGURE 3           BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 51

FIGURE 4           BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  AND REGION  51

2.2         MARKET SIZE ESTIMATION       52

FIGURE 5           REVENUE SHARE ANALYSIS       52

FIGURE 6           CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS   53

FIGURE 7           TOP-DOWN APPROACH             54

2.3         MARKET BREAKDOWN AND DATA TRIANGULATION    55

FIGURE 8           DATA TRIANGULATION METHODOLOGY         55

2.4         MARKET SHARE ANALYSIS         56

2.5         STUDY ASSUMPTIONS  56

2.5.1      MARKET ASSUMPTIONS             56

2.5.2      GROWTH RATE ASSUMPTIONS 56

2.6         RESEARCH LIMITATIONS           57

2.6.1      METHODOLOGY-RELATED LIMITATIONS         57

2.6.2      SCOPE-RELATED LIMITATIONS             57

2.7         RISK ASSESSMENT         57

TABLE 1             RISK ASSESSMENT: IMMUNOASSAY MARKET     57

2.8         IMPACT OF RECESSION ON IMMUNOASSAY MARKET    57

3            EXECUTIVE SUMMARY 59

FIGURE 9           IMMUNOASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)           59

FIGURE 10         IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION) 60

FIGURE 11         IMMUNOASSAY MARKET, BY SPECIMEN, 2023 VS. 2028 (USD BILLION)           61

FIGURE 12         IMMUNOASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION)           62

FIGURE 13         IMMUNOASSAY MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)           63

FIGURE 14         GEOGRAPHICAL SNAPSHOT: IMMUNOASSAY MARKET 64

4            PREMIUM INSIGHTS      65

4.1         IMMUNOASSAY MARKET OVERVIEW     65

FIGURE 15         RISING INCIDENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET            65

4.2         NORTH AMERICA: IMMUNOASSAY MARKET,  BY PRODUCT AND COUNTRY (2022)           66

FIGURE 16         REAGENTS & KITS AND US DOMINATED NORTH AMERICAN IMMUNOASSAY MARKET IN 2022            66

4.3         GEOGRAPHICAL SNAPSHOT: IMMUNOASSAY MARKET,  2023–2028              67

FIGURE 17         CHINA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD       67

4.4         REGIONAL MIX: IMMUNOASSAY MARKET, 2021–2028     68

FIGURE 18         ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING STUDY PERIOD              68

4.5         DEVELOPED VS. EMERGING ECONOMIES:  IMMUNOASSAY MARKET, 2023–2028          69

FIGURE 19         EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD     69

5            MARKET OVERVIEW     70

5.1         INTRODUCTION            70

5.2         MARKET DYNAMICS     70

FIGURE 20         DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: IMMUNOASSAY MARKET           70

5.2.1      DRIVERS            71

5.2.1.1   Increasing incidence of chronic and infectious diseases 71

FIGURE 21         INCREASING INCIDENCES OF DIABETES (IN MILLION) 71

5.2.1.1.1 Growing use of immunoassays in oncology    72

TABLE 2             GLOBAL INCIDENCE OF MAJOR CANCERS IN MEN, 2020 72

TABLE 3             GLOBAL INCIDENCE OF MAJOR CANCERS IN WOMEN, 2020              73

5.2.1.1.2 Increasing use of immunoassays in diagnostic applications         73

TABLE 4             TIME REQUIRED FOR DRUG DETECTION BY URINE TESTING              73

5.2.1.1.3 Growing geriatric population           74

FIGURE 22         GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (IN MILLION)   74

5.2.1.2   Increasing need for blood donations 75

5.2.1.3   Growth in biotechnology & biopharmaceutical industries           75

5.2.1.4   Increasing adoption of immunoassay-based POC testing and rapid testing              76

5.2.1.5   Supportive government regulatory policies and initiatives          77

5.2.1.6   Increased drug abuse and use of cannabis      77

5.2.2      RESTRAINTS     78

5.2.2.1   Stringent approval criteria for immunoassay instruments and consumables              78

5.2.2.2   Technical problems in immunoassay kits        78

5.2.3      OPPORTUNITIES           79

5.2.3.1   Increasing growth opportunities in emerging economies            79

5.2.3.2   Importance of companion diagnostics            80

TABLE 5             COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED, 2018–2022  80

5.2.3.3   Development of condition-specific biomarkers and tests            81

TABLE 6             NEW TESTS LAUNCHED BY KEY PLAYERS, 2019–2023      81

5.2.3.4   Integration of microfluidics in immunoassays 82

TABLE 7             LAB-ON-A-CHIP IMMUNOASSAY DEVICES/CHIPS/SYSTEMS OFFERED BY KEY PLAYERS        82

5.2.3.5   Improved immunoassay diagnostic technologies          83

5.2.4      CHALLENGES   83

5.2.4.1   Design challenges, complexities, and low quality of antibodies   83

5.2.4.2   Dearth of skilled professionals         83

5.2.4.3   Unfavorable reimbursement scenario             84

5.3         REGULATORY ANALYSIS            84

5.3.1      NORTH AMERICA          84

5.3.1.1   US         84

TABLE 8             US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS    84

FIGURE 23         US: REGULATORY PROCESS FOR IVD DEVICES  85

5.3.1.2   Canada  86

FIGURE 24         CANADA: REGULATORY PROCESS FOR IVD DEVICES     86

5.3.2      EUROPE             86

TABLE 9             EUROPE: CLASSIFICATION OF IVD DEVICES      86

5.3.2.1   Russia    87

TABLE 10           RUSSIA: CLASSIFICATION OF IVD DEVICES        87

5.3.3      ASIA PACIFIC    88

5.3.3.1   Japan     88

FIGURE 25         JAPAN: REGULATORY PROCESS FOR IVD DEVICES         88

TABLE 11           JAPAN: CLASSIFICATION OF IVD REAGENTS      89

TABLE 12           JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS           89

5.3.3.2   China     89

TABLE 13           CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS           89

5.3.3.3   India      90

FIGURE 26         INDIA: REGULATORY PROCESS FOR IVD DEVICES          90

5.3.3.4   Indonesia             91

TABLE 14           INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES              91

5.3.3.5   South Korea        91

TABLE 15           SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS          91

5.3.4      LATIN AMERICA             92

5.3.4.1   Mexico  92

FIGURE 27         MEXICO: REGULATORY PROCESS FOR IVD DEVICES      92

TABLE 16           MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS           92

5.3.4.2   Brazil     93

FIGURE 28         BRAZIL: REGULATORY PROCESS FOR IVD DEVICES       93

5.3.5      MIDDLE EAST  93

5.3.5.1   Saudi Arabia        94

TABLE 17           SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS          94

5.3.6      AFRICA 94

5.4         TECHNOLOGY ANALYSIS           94

TABLE 18           CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES   95

TABLE 19           RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET    95

5.5         TRADE ANALYSIS          96

5.5.1      TRADE ANALYSIS FOR IMMUNOASSAY PRODUCTS        96

TABLE 20           IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION) 96

TABLE 21           EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION) 96

5.6         PATENT ANALYSIS        97

5.7         VALUE CHAIN ANALYSIS            98

FIGURE 29         VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES      98

5.8         SUPPLY CHAIN ANALYSIS          99

FIGURE 30         SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES 99

5.9         ECOSYSTEM/MARKET MAP       100

FIGURE 31         ECOSYSTEM/MARKET MAP: IMMUNOASSAY MARKET   100

5.9.1      ROLE IN ECOSYSTEM    100

5.9.2      KEY PLAYERS IN IMMUNOASSAY MARKET         101

5.10       PORTER’S FIVE FORCES ANALYSIS         102

TABLE 22           PORTER’S FIVE FORCES 102

5.10.1    INTENSITY OF COMPETITIVE RIVALRY 102

5.10.2    BARGAINING POWER OF SUPPLIERS     102

5.10.3    BARGAINING POWER OF BUYERS           102

5.10.4    THREAT OF SUBSTITUTES         102

5.10.5    THREAT FROM NEW ENTRANTS             103

5.11       KEY CONFERENCES & EVENTS IN 2023–2024       103

TABLE 23           KEY CONFERENCES & EVENTS IN 2023–2024       103

5.12       PRICING ANALYSIS        104

TABLE 24           PRICE RANGE FOR IMMUNOASSAY PRODUCTS 104

5.13       KEY STAKEHOLDERS & BUYING CRITERIA          105

5.13.1    KEY STAKEHOLDERS IN BUYING PROCESS         105

FIGURE 32         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER    105

TABLE 25           INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS              105

5.13.2    BUYING CRITERIA         106

FIGURE 33         KEY BUYING CRITERIA FOR TOP END USERS     106

TABLE 26           KEY BUYING CRITERIA, BY TOP END USER         106

5.14       TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 107

6            IMMUNOASSAY MARKET, BY PRODUCT             108

6.1         INTRODUCTION            109

TABLE 27           IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          109

6.2         REAGENTS & KITS          109

TABLE 28           KEY REAGENTS & KITS AVAILABLE        110

TABLE 29           IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION)          111

TABLE 30           IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)          111

6.2.1      ELISA REAGENTS & KITS             112

6.2.1.1   Increased use of high-throughput screening in drug discovery programs to drive segment 112

TABLE 31           ELISA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)          113

6.2.2      RAPID TEST REAGENTS & KITS 113

6.2.2.1   High demand for rapid test reagents & kits in remote areas for preliminary screening tests to drive segment       113

TABLE 32           RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION) 114

6.2.3      ELISPOT REAGENTS & KITS       114

6.2.3.1   High sensitivity, functionality, and adaptability of ELISpot technology to drive segment 114

TABLE 33           ELISPOT REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION) 115

6.2.4      CLIA REAGENTS & KITS 115

6.2.4.1   Better diagnosis and higher specificity to drive segment             115

TABLE 34           CLIA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)          116

6.2.5      IFA REAGENTS & KITS   116

6.2.5.1   Better adaptability in clinical diagnostics and medicine to drive segment  116

TABLE 35           IFA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)          117

6.2.6      WESTERN BLOT REAGENTS & KITS        117

6.2.6.1   Western blotting reagents & kits to be considered gold standard for COVID-19 test result validation          117

TABLE 36           WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)     118

6.2.7      OTHER REAGENTS & KITS          118

TABLE 37           OTHER REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION) 119

6.3         ANALYZERS      119

TABLE 38           KEY ANALYZERS AVAILABLE     120

TABLE 39           IMMUNOASSAY MARKET FOR ANALYZERS, BY REGION, 2021–2028 (USD MILLION)     121

6.3.1      IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE      121

TABLE 40           IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION) 122

6.3.1.1   Open-ended systems          122

6.3.1.1.1 Better flexibility and wider availability to drive segment             122

TABLE 41           OPEN-ENDED SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION)          122

6.3.1.2   Closed-ended systems        123

6.3.1.2.1 Higher precision and better automation to drive segment           123

TABLE 42           CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION) 123

6.3.2      IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE              123

TABLE 43           IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)        123

6.3.2.1   Rental purchase   124

6.3.2.1.1 Increased convenience and lack of liability to drive segment       124

TABLE 44           RENTAL PURCHASE MARKET, BY REGION, 2021–2028 (USD MILLION)          124

6.3.2.2   Outright purchase              124

6.3.2.2.1 Inflated cost of immunoassay testing technologies to limit market            124

TABLE 45           OUTRIGHT PURCHASE MARKET, BY REGION, 2021–2028 (USD MILLION)          125

7            IMMUNOASSAY MARKET, BY TECHNOLOGY     126

7.1         INTRODUCTION            127

TABLE 46           IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          127

7.2         ELISA   127

7.2.1      BETTER SENSITIVITY AND QUICKER RESULTS TO DRIVE MARKET              127

TABLE 47           KEY ELISA TECHNOLOGIES AVAILABLE 128

TABLE 48           IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2021–2028 (USD MILLION) 129

7.3         CLIA     129

7.3.1      GOOD SPECIFICITY, WIDE LINEAR RANGE, AND HIGH SENSITIVITY TO DRIVE MARKET 129

TABLE 49           IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2021–2028 (USD MILLION) 130

7.4         IFA        130

7.4.1      IFA TO DIAGNOSE ANTIBODIES AND ANALYZE SMALL BIOLOGICAL AND NON-BIOLOGICAL MOLECULES    130

TABLE 50           IMMUNOASSAY MARKET FOR IFA, BY REGION, 2021–2028 (USD MILLION)          131

7.5         RAPID TESTS    131

7.5.1      FASTER RESULTS AND EASE OF USE TO DRIVE MARKET             131

TABLE 51           KEY RAPID TESTS AVAILABLE   131

TABLE 52           IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2021–2028 (USD MILLION)     132

7.6         WESTERN BLOTTING   132

7.6.1      ABILITY TO DETECT AND CONFIRM ANTIBODIES OF RETROVIRUSES TO DRIVE MARKET       132

TABLE 53           WESTERN BLOTTING SYSTEMS AVAILABLE       133

TABLE 54           IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION,  2021–2028 (USD MILLION)     133

7.7         ELISPOT            133

7.7.1      HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY TO DRIVE MARKET            133

TABLE 55           IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2021–2028 (USD MILLION) 134

7.8         OTHER TECHNOLOGIES            134

TABLE 56           IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION,  2021–2028 (USD MILLION)     135

8            IMMUNOASSAY MARKET, BY SPECIMEN             136

8.1         INTRODUCTION            137

TABLE 57           IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)          137

8.2         BLOOD 137

8.2.1      HIGH RELIABILITY AND ADVANCEMENTS IN HEALTHCARE SYSTEM TO DRIVE MARKET       137

TABLE 58           IMMUNOASSAY MARKET FOR BLOOD, BY REGION, 2021–2028 (USD MILLION) 138

8.3         SALIVA 139

8.3.1      DEVELOPMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO DRIVE MARKET            139

TABLE 59           IMMUNOASSAY MARKET FOR SALIVA, BY REGION, 2021–2028 (USD MILLION) 139

8.4         URINE  139

8.4.1      INCREASING USE BY LAW ENFORCEMENT AGENCIES AND RISING PREVALENCE OF KIDNEY DISEASES TO DRIVE MARKET             139

TABLE 60           IMMUNOASSAY MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION) 140

8.5         OTHER SPECIMENS       140

TABLE 61           IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION,  2021–2028 (USD MILLION)          141

9            IMMUNOASSAY MARKET, BY APPLICATION       142

9.1         INTRODUCTION            143

TABLE 62           IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          143

9.2         INFECTIOUS DISEASES 144

9.2.1      RISING PREVALENCE OF CHRONIC INFECTIOUS DISEASES TO DRIVE MARKET            144

TABLE 63           IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION,  2021–2028 (USD MILLION)     144

9.3         ENDOCRINOLOGY        145

9.3.1      RISING INCIDENCE OF DIABETES TO DRIVE MARKET   145

TABLE 64           IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION)          145

9.4         CARDIOLOGY  146

9.4.1      HIGH BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET              146

TABLE 65           KEY PRODUCTS FOR CARDIOLOGY APPLICATIONS       146

TABLE 66           IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION)     147

9.5         AUTOIMMUNE DISORDERS       147

9.5.1      HIGH INCIDENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET   147

TABLE 67           IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION,  2021–2028 (USD MILLION)     148

9.6         ALLERGY DIAGNOSTICS            148

9.6.1      GROWING PREVALENCE OF ALLERGIES TO DRIVE MARKET      148

TABLE 68           IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION,  2021–2028 (USD MILLION)     149

9.7         ONCOLOGY      149

9.7.1      RISING BURDEN OF CANCER AND GROWING EMPHASIS ON EARLY DETECTION TO DRIVE MARKET            149

TABLE 69           INCREASING INCIDENCE OF CANCER, BY REGION, 2021 VS. 2030 VS. 2040 (MILLION)       150

TABLE 70           IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)     150

9.8         BONE & MINERAL DISORDERS  151

9.8.1      INCREASING PREVALENCE OF BONE DISEASES TO DRIVE MARKET              151

TABLE 71           KEY PRODUCTS FOR BONE & MINERAL DISORDERS      151

TABLE 72           IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION,  2021–2028 (USD MILLION)             152

9.9         DRUG MONITORING AND TESTING      152

9.9.1      RISING DRUG ABUSE AND INCREASING ILLICIT DRUG CONSUMPTION TO DRIVE MARKET       152

TABLE 73           KEY PRODUCTS FOR DRUG MONITORING         153

TABLE 74           KEY IMMUNOASSAY PRODUCTS FOR DRUG TESTING   153

TABLE 75           IMMUNOASSAY MARKET FOR DRUG MONITORING AND TESTING,  BY REGION, 2021–2028 (USD MILLION)         154

9.10       BLOOD SCREENING      154

9.10.1    RISING NUMBER OF BLOOD DONATIONS TO DRIVE MARKET   154

TABLE 76           IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION,  2021–2028 (USD MILLION)          155

9.11       NEWBORN SCREENING 155

9.11.1    TECHNOLOGICAL ADVANCEMENTS AND INCREASED GOVERNMENT SUPPORT TO DRIVE MARKET   155

TABLE 77           KEY PRODUCTS FOR NEWBORN SCREENING     155

TABLE 78           IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION,  2021–2028 (USD MILLION)     156

9.12       OTHER APPLICATIONS 156

TABLE 79           IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION,  2021–2028 (USD MILLION)     157

10          IMMUNOASSAY MARKET, BY END USER 158

10.1       INTRODUCTION            159

TABLE 80           IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)          159

10.2       HOSPITALS & CLINICS  159

10.2.1    GROWING PATIENT POPULATION AND TESTING VOLUME TO DRIVE MARKET            159

TABLE 81           IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION,  2021–2028 (USD MILLION)     161

10.3       CLINICAL LABORATORIES         161

10.3.1    INCREASING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET            161

TABLE 82           IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION,  2021–2028 (USD MILLION)     162

10.4       PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS    162

10.4.1    GROWING DRUG DISCOVERY AND INCREASING R&D INVESTMENTS TO DRIVE MARKET       162

TABLE 83           IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)  163

10.5       HOME CARE SETTINGS 164

10.5.1    RISING UTILIZATION OF POC DIAGNOSTICS AND AT-HOME ANTIGEN DIAGNOSIS TO DRIVE MARKET 164

TABLE 84           IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION,  2021–2028 (USD MILLION)     164

10.6       BLOOD BANKS 164

10.6.1    RISING DEMAND FOR BLOOD AND INCREASING NUMBER OF ACCIDENTS TO DRIVE MARKET             164

TABLE 85           IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2021–2028 (USD MILLION)          165

10.7       RESEARCH & ACADEMIC LABORATORIES           165

10.7.1    RISING NUMBER OF MEDICAL COLLEGES AND UNIVERSITIES TO DRIVE MARKET 165

TABLE 86           IMMUNOASSAY MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 166

11          IMMUNOASSAY MARKET, BY REGION   167

11.1       INTRODUCTION            168

TABLE 87           IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION)          168

11.2       NORTH AMERICA          168

FIGURE 34         NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT              169

TABLE 88           NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          170

TABLE 89           NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          170

TABLE 90           NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)            171

TABLE 91           NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)         171

TABLE 92           NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)   172

TABLE 93          NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)          172

TABLE 94           NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)          173

TABLE 95           NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)          173

TABLE 96           NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)          174

11.2.1    NORTH AMERICA: RECESSION IMPACT 174

11.2.2    US         175

11.2.2.1 High healthcare expenditure and growth in geriatric population to drive market              175

TABLE 97           US: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          176

TABLE 98           US: IMMUNOASSAY ASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)          176

TABLE 99           US: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          177

TABLE 100         US: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 177

TABLE 101         US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 178

TABLE 102         US: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)          178

TABLE 103         US: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 179

TABLE 104         US: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)          180

11.2.3    CANADA            180

11.2.3.1 Increasing government support and rising incidence of chronic diseases to drive market   180

TABLE 105         CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 181

TABLE 106         CANADA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)          182

TABLE 107         CANADA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          182

TABLE 108         CANADA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 183

TABLE 109         CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)     183

TABLE 110         CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 184

TABLE 111         CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)     184

TABLE 112         CANADA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 185

11.3       EUROPE             185

TABLE 113         EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 186

TABLE 114         EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 186

TABLE 115         EUROPE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)          187

TABLE 116         EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          187

TABLE 117         EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 188

TABLE 118         EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)     188

TABLE 119         EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 189

TABLE 120         EUROPE: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)     189

TABLE 121         EUROPE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 190

11.3.1    EUROPE: RECESSION IMPACT   190

11.3.2    GERMANY         191

11.3.2.1 Germany to dominate European immunoassay market during forecast period              191

TABLE 122         GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 192

TABLE 123         GERMANY: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)    192

TABLE 124        GERMANY: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          193

TABLE 125         GERMANY: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 193

TABLE 126         GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)          194

TABLE 127         GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 194

TABLE 128         GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)     195

TABLE 129         GERMANY: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 196

11.3.3    ITALY   196

11.3.3.1 Growing geriatric population and increasing support for research to drive market              196

TABLE 130         ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          197

TABLE 131         ITALY: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)          197

TABLE 132         ITALY: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          198

TABLE 133         ITALY: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 198

TABLE 134         ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)     199

TABLE 135         ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 199

TABLE 136         ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 200

TABLE 137         ITALY: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)          201

11.3.4    FRANCE             201

11.3.4.1 Rising use of POC testing and favorable reimbursement policies to drive market              201

TABLE 138         FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 202

TABLE 139         FRANCE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)          202

TABLE 140         FRANCE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          203

TABLE 141         FRANCE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 203

TABLE 142         FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)     204

TABLE 143         FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 204

TABLE 144         FRANCE: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)     205

TABLE 145         FRANCE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 206

11.3.5    SPAIN   206

11.3.5.1 Increasing adoption of technologically advanced immunoassay systems to drive market   206

TABLE 146         SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          207

TABLE 147         SPAIN: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)          207

TABLE 148         SPAIN: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          208

TABLE 149         SPAIN: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 208

TABLE 150         SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 209

TABLE 151         SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 209

TABLE 152         SPAIN: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION) 210

TABLE 153         SPAIN: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)          211

11.3.6    UK         211

11.3.6.1 Government support for disease diagnostics and favorable investment scenario to drive market        211

TABLE 154         UK: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          212

TABLE 155         UK: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)          213

TABLE 156         UK: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          213

TABLE 157         UK: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)        214

TABLE 158         UK: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION) 214

TABLE 159         UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)          215

TABLE 160         UK: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION) 215

TABLE 161         UK: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)          216

11.3.7    RUSSIA 216

11.3.7.1 Lack of reimbursement and delays in approval to limit market   216

TABLE 162         RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 217

TABLE 163         RUSSIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)          217

TABLE 164         RUSSIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          218

TABLE 165         RUSSIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 218

TABLE 166         RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)     219

TABLE 167         RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 219

TABLE 168         RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 220

TABLE 169         RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 221

11.3.8    REST OF EUROPE           221

TABLE 170         REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          222

TABLE 171         REST OF EUROPE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)        222

TABLE 172         REST OF EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)    223

TABLE 173         REST OF EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)          223

TABLE 174         REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)          224

TABLE 175         REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)          224

TABLE 176         REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)          225

TABLE 177         REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)          226

11.4       ASIA PACIFIC    226

FIGURE 35         ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT       227

TABLE 178         ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)     228

TABLE 179         ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)     228

TABLE 180         ASIA PACIFIC: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)    229

TABLE 181         ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          229

TABLE 182         ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 230

TABLE 183         ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)          230

TABLE 184         ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)     231

TABLE 185         ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)          231

TABLE 186         ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)     232

11.4.1    ASIA PACIFIC: RECESSION IMPACT        232

11.4.2    JAPAN  232

11.4.2.1 Increasing investments in healthcare technologies and research activities to drive market   232

TABLE 187         JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 233

TABLE 188         JAPAN: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)          234

TABLE 189         JAPAN: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          234

TABLE 190         JAPAN: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 235

TABLE 191         JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)     235

TABLE 192         JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 236

TABLE 193         JAPAN: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)     236

TABLE 194         JAPAN: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)          237

11.4.3    CHINA  237

11.4.3.1 Increasing government investment and rising geriatric population to drive market              237

TABLE 195         CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 238

TABLE 196         CHINA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)          239

TABLE 197         CHINA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          239

TABLE 198         CHINA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 240

TABLE 199         CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)     240

TABLE 200         CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 241

TABLE 201         CHINA: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)     241

TABLE 202         CHINA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 242

11.4.4    INDIA   242

11.4.4.1 Growing medical tourism and healthcare infrastructure to drive market   242

TABLE 203         INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          243

TABLE 204         INDIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)          244

TABLE 205         INDIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          244

TABLE 206         INDIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 245

TABLE 207         INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)     245

TABLE 208         INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)          246

TABLE 209         INDIA: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION) 246

TABLE 210         INDIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)          247

11.4.5    AUSTRALIA       247

11.4.5.1 Increasing incidence of cancer and rising blood donations to drive market              247

TABLE 211         AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 248

TABLE 212         AUSTRALIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)    248

TABLE 213         AUSTRALIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          249

TABLE 214         AUSTRALIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 249

TABLE 215         AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)          250

TABLE 216         AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 250

TABLE 217         AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)          251

TABLE 218         AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 251

11.4.6    SOUTH KOREA 252

11.4.6.1 Rising healthcare spending and investments in research to drive market  252

TABLE 219         SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)     252

TABLE 220         SOUTH KOREA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)        253

TABLE 221         SOUTH KOREA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          253

TABLE 222         SOUTH KOREA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 254

TABLE 223         SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)          254

TABLE 224         SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)     255

TABLE 225         SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)          255

TABLE 226         SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)     256

11.4.7    INDONESIA       256

11.4.7.1 Increasing geriatric population and favorable government healthcare policies to drive market        256

TABLE 227         INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 257

TABLE 228         INDONESIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)    257

TABLE 229         INDONESIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          258

TABLE 230         INDONESIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 258

TABLE 231         INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)          259

TABLE 232         INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)     259

TABLE 233         INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)          260

TABLE 234         INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 260

11.4.8    REST OF ASIA PACIFIC  261

TABLE 235        REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT,  2021–2028 (USD MILLION)          262

TABLE 236         REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)            262

TABLE 237         REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)         263

TABLE 238         REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 263

TABLE 239         REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)       264

TABLE 240        REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN,  2021–2028 (USD MILLION)          264

TABLE 241         REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)        265

TABLE 242        REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER,  2021–2028 (USD MILLION)          266

11.5       LATIN AMERICA             266

TABLE 243         LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          267

TABLE 244         LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          267

TABLE 245         LATIN AMERICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)        268

TABLE 246         LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)    268

TABLE 247         LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION)          269

TABLE 248         LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          269

TABLE 249         LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)          270

TABLE 250         LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)          270

TABLE 251         LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)     271

11.5.1    LATIN AMERICA: RECESSION IMPACT   271

11.5.2    BRAZIL 271

11.5.2.1 Brazil commanded largest share in Latin American immunoassay market in 2022              271

TABLE 252         BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 272

TABLE 253         BRAZIL: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)          273

TABLE 254         BRAZIL: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          273

TABLE 255         BRAZIL: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 274

TABLE 256         BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)     274

TABLE 257         BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 275

TABLE 258         BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 275

TABLE 259         BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 276

11.5.3    MEXICO             276

11.5.3.1 Increasing geriatric population and rising medical tourism to drive market              276

TABLE 260         MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 277

TABLE 261         MEXICO: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)          277

TABLE 262         MEXICO: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)          278

TABLE 263         MEXICO: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 278

TABLE 264         MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)     279

TABLE 265         MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION) 279

TABLE 266         MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)     280

TABLE 267         MEXICO: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 280

11.5.4    REST OF LATIN AMERICA          281

TABLE 268         REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT,  2021–2028 (USD MILLION) 281

TABLE 269         REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)            282

TABLE 270         REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)         282

TABLE 271         REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)   283

TABLE 272         REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)       283

TABLE 273         REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN,  2021–2028 (USD MILLION) 284

TABLE 274         REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)        284

TABLE 275         REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER,  2021–2028 (USD MILLION)          285

11.6       MIDDLE EAST & AFRICA             285

11.6.1    LACK OF SKILLED LAB PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT GROWTH            285

11.6.2    MIDDLE EAST & AFRICA: RECESSION IMPACT   286

TABLE 276         MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT,  2021–2028 (USD MILLION) 286

TABLE 277         MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE,  2021–2028 (USD MILLION)            286

TABLE 278         MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE,  2021–2028 (USD MILLION)         287

TABLE 279         MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,  2021–2028 (USD MILLION) 287

TABLE 280         MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)       288

TABLE 281         MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN,  2021–2028 (USD MILLION) 288

TABLE 282         MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)        289

TABLE 283         MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER,  2021–2028 (USD MILLION)          290

12          COMPETITIVE LANDSCAPE       291

12.1       OVERVIEW        291

12.2       KEY PLAYER STRATEGIES/RIGHT TO WIN          291

12.2.1    OVERVIEW OF KEY STRATEGIES ADOPTED BY MAJOR PLAYERS              291

TABLE 284         OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOASSAY MARKET      291

12.3       REVENUE ANALYSIS      292

FIGURE 36         REVENUE ANALYSIS OF KEY PLAYERS   293

12.4       MARKET SHARE ANALYSIS         293

TABLE 285         DEGREE OF COMPETITION IN IMMUNOASSAY MARKET              294

FIGURE 37         IMMUNOASSAY MARKET SHARE, BY KEY PLAYER (2022)              294

12.5       COMPANY EVALUATION MATRIX          295

12.5.1    STARS  295

12.5.2    EMERGING LEADERS    295

12.5.3    PERVASIVE PLAYERS     295

12.5.4    PARTICIPANTS 295

FIGURE 38         COMPANY EVALUATION MATRIX, 2022 296

12.5.5    COMPANY FOOTPRINT 296

TABLE 286         OVERALL FOOTPRINT  296

TABLE 287         PRODUCT FOOTPRINT 297

TABLE 288         REGIONAL FOOTPRINT             298

12.6       START-UP/SME EVALUATION MATRIX 299

12.6.1    PROGRESSIVE COMPANIES       299

12.6.2    RESPONSIVE COMPANIES          299

12.6.3    DYNAMIC COMPANIES 299

12.6.4    STARTING BLOCKS       299

FIGURE 39         START-UP/SME EVALUATION MATRIX, 2022      300

12.6.5    COMPETITIVE BENCHMARKING            301

TABLE 289         KEY START-UPS/SMES IN IMMUNOASSAY MARKET        301

12.7       COMPETITIVE SCENARIOS AND TRENDS           302

12.7.1    KEY PRODUCT LAUNCHES AND APPROVALS    302

TABLE 290         KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2020–SEPTEMBER 2023           302

12.7.2    KEY DEALS        303

TABLE 291         KEY DEALS, JANUARY 2020–SEPTEMBER 2023     303

12.7.3    OTHER KEY DEVELOPMENTS   304

TABLE 292         OTHER KEY DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2023              304

13          COMPANY PROFILES    305

13.1       KEY PLAYERS   305

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*

13.1.1    ABBOTT LABORATORIES           305

TABLE 293         ABBOTT LABORATORIES: COMPANY OVERVIEW            305

FIGURE 40         ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 306

13.1.2    F. HOFFMANN-LA ROCHE LTD. 310

TABLE 294         F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 310

FIGURE 41         F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)              311

13.1.3    SIEMENS HEALTHINEERS AG    317

TABLE 295         SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW     317

FIGURE 42         SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)              318

13.1.4    DANAHER CORPORATION         322

TABLE 296         DANAHER CORPORATION: COMPANY OVERVIEW         322

FIGURE 43         DANAHER CORPORATION: COMPANY SNAPSHOT (2022)              323

13.1.5    THERMO FISHER SCIENTIFIC INC.          327

TABLE 297         THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW              327

FIGURE 44         THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)   328

13.1.6    REVVITY            332

TABLE 298         REVVITY: COMPANY OVERVIEW            332

FIGURE 45         REVVITY: COMPANY SNAPSHOT (2022) 332

13.1.7    BECTON, DICKINSON AND COMPANY  336

TABLE 299         BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW              336

FIGURE 46         BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)   337

13.1.8    DIASORIN S.P.A.             340

TABLE 300         DIASORIN S.P.A.: COMPANY OVERVIEW 340

FIGURE 47         DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)  341

13.1.9    BIO-RAD LABORATORIES, INC. 344

TABLE 301         BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW  344

FIGURE 48         BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)              345

13.1.10  QUIDELORTHO CORPORATION             348

TABLE 302         QUIDELORTHO CORPORATION: COMPANY OVERVIEW 348

FIGURE 49         QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)              349

13.1.11  BIOMÉRIEUX    355

TABLE 303         BIOMÉRIEUX: COMPANY OVERVIEW     355

FIGURE 50         BIOMÉRIEUX: COMPANY SNAPSHOT (2022)       356

13.1.12  QIAGEN N.V.     359

TABLE 304         QIAGEN N.V.: COMPANY OVERVIEW     359

FIGURE 51         QIAGEN N.V.: COMPANY SNAPSHOT (2022)        360

13.1.13  SYSMEX CORPORATION             362

TABLE 305         SYSMEX CORPORATION: COMPANY OVERVIEW 362

FIGURE 52         SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)  363

13.1.14  AGILENT TECHNOLOGIES, INC.             366

TABLE 306         AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 366

FIGURE 53         AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)              367

13.1.15  SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.  369

TABLE 307         SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW  369

FIGURE 54         SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2022)    369

13.2       OTHER PLAYERS           371

13.2.1    MERCK KGAA   371

13.2.2    MERIDIAN BIOSCIENCE 372

13.2.3    BIO-TECHNE    373

13.2.4    CELLABS           374

13.2.5    ABNOVA CORPORATION           375

13.2.6    J. MITRA & CO. PVT. LTD.           375

13.2.7    TOSOH CORPORATION (TOSOH BIOSCIENCE) 376

13.2.8    CELL SCIENCES 376

13.2.9    ENZO BIOCHEM             377

13.2.10  CREATIVE DIAGNOSTICS           378

13.2.11  BOSTER BIOLOGICAL TECHNOLOGY   378

13.2.12  ELABSCIENCE  379

13.2.13  WAK-CHEMIE MEDICAL             379

13.2.14  SERACARE LIFESCIENCES INC.  380

13.2.15  EPITOPE DIAGNOSTICS             380

13.2.16  KAMIYA BIOMEDICAL COMPANY           381

13.2.17  GYROS PROTEIN TECHNOLOGIES         381

13.2.18  TRIVITRON HEALTHCARE         382

13.2.19  INBIOS INTERNATIONAL, INC.  382

13.2.20  MACCURA BIOTECHNOLOGY CO., LTD.             383

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

14          APPENDIX         384

14.1       DISCUSSION GUIDE      384

14.2       KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL             389

14.3       CUSTOMIZATION OPTIONS      391

14.4       RELATED REPORTS       391

14.5       AUTHOR DETAILS         394


    주문/문의폼

    • 리포트 제목은 자동으로 입력됩니다.

    • *항목은 필수항목입니다.

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com